Dr. Reddy's Reports Q2 Margins At 20.6%, Reaffirms FY27 EBITDA Margin Forecast Above 20%

Dr. Reddy’s posted Q2 FY27 EBITDA margins of 20.6% alongside ₹1,783 crore in EBITDA. Strong growth in domestic and emerging market formulations helped offset price erosion in the US, allowing management to confirm its target of sustaining FY27 EBITDA margins above 20%.